Decipher Biosciences, Inc.
10355 Science Center Drive
90 articles with Decipher Biosciences, Inc.
Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers, today announced publication of the results
Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth
eviCore Clinical Guidelines Incorporate Decipher Prostate into New Medical Necessity Criteria for Prostate Cancer Patients
Decipher Prostate is the first and only genomic test recognized by eviCore for the management of prostate cancer patients after surgery
Decipher Biosciences Achieves Major Medicare Milestone with Expansion in Coverage for Decipher Prostate Genomic Testing
First Precision Oncology Company to Receive Medicare Coverage for All Localized Prostate Cancer Patients Being Considered for Treatment [25-September-2020] SAN DIEGO , Sept. 25, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced that Palmet
Decipher Identifies a Molecular Subtype Most Likely to Benefit from Neoadjuvant KEYTRUDA Immunotherapy in Bladder Cancer Patients
Decipher Biosciences announced that patients with the molecular subtype Basal Claudin Low, identified by the Decipher Bladder test and studied in the PURE-01 clinical trial, received the most benefit in progression-free survival from neoadjuvant KEYTRUDA immunotherapy in patients with muscle-invasive bladder cancer.
Decipher Prostate RP Identifies Patients Likely to Benefit from Hormonal Therapy in Men with Recurrent Prostate Cancer
Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced that Decipher Prostate RP, studied in patients from the phase III, randomized controlled trial, RTOG 96-01, demonstrated the ability to accurately identify which prostate cancer patients with recurrent disease benefit most from anti-androgen hormonal therapy
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced that a Decipher GRID molecular subtyping signature, studied in patients from the phase III, randomized controlled trial, CHAARTED
Decipher Biosciences Announces Addition of Dr. Robert S. Epstein as Chairman and Kathy Hibbs, Esq. to its Board of Directors
Decipher Biosciences announced the appointments of Robert S. Epstein, M.D., and Kathy Hibbs, Esq. to its Board of Directors. Dr. Epstein was also elected Chairman of the Board.
Decipher Biosciences Announces Publication of a Prospective Clinical Study Demonstrating that the Use of Decipher Prostate RP Guides Post-Operative Management Decisions and Improves Patient Outcomes
Decipher Biosciences, a commercial stage precision oncology company initially focused on urologic cancers, today announced that recent findings from a prospective study demonstrate the clinical utility of the Decipher Prostate Genomic Classifier after radical prostatectomy.
Decipher Biosciences, a leader in the field of urologic cancer genomics, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), issued a final local coverage determination (LCD) for use of Decipher® Prostate Biopsy in men diagnosed with favorable and unfavorable intermediate-risk prostate cancer.
Decipher Biosciences Announces Research Collaboration with Dendreon to Identify Genomic Drivers of Patient Response to Sipuleucel-T
Decipher Biosciences, a leader in the field of urologic cancer genomics, today announced a research collaboration with Dendreon Pharmaceuticals
QuantuMDx Group Ltd, the UK-based multinational molecular diagnostics company, today announced two key leadership appointments. Dr Allan Brown has been appointed Chief Operating Officer and David Matthews joins as Chief Financial Officer.
GenomeDx Announces Medicare Draft Local Coverage Determination (LCD) for Decipher Prostate Biopsy Genomic Classifier
Draft LCD for use of Decipher in men with very low and low NCCN risk prostate cancer
GenomeDx Biosciences and Pathnostics today announced the launch of the next generation Guidance testing for patients suffering from simple cystitis.
GenomeDx Biosciences' Genomic Data Featured at 2018 AUA Conference in Multiple Prostate and Bladder Cancer Presentations
-- Presentations Highlight Versatility of Decipher Tests and Decipher GRID Technology Platform --
GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development
GenomeDx Biosciences announced a research collaboration with Janssen Pharmaceuticals.
GenomeDx Biosciences' Decipher Tests and Decipher GRID to be Featured in Multiple Presentations at 2018 Genitourinary Cancers Symposium
The 2018 GU Cancers Symposium is the premier scientific and educational meeting .
GenomeDx Biosciences’s Decipher Cancer Classifier Tests And Genomic Database To Be Featured In Multiple Presentations At ASTRO 2017
GenomeDx Biosciences To Distribute Pathnostics' Guidance UGx Test For Urinary Tract Infection And Guidance PRx Test For Prostatitis
GenomeDx Biosciences Launches Hereditary Cancer Risk Genetic Testing By Color For Prostate Cancer Patients And Families